[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615640":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":22,"responsibleParty":46,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Ukrainian Society of Clinical Oncology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Endo-vac cohort",null,"Patients who are diagnosed with asophago-jejunal anastomotic leakage will undergo endoscopic vacuum therapy. Local source control may be additionally achieved with para-anastomotic drains.",[13],{"name":14,"affiliation":15,"role":16},"Oleksii Dobrzhanskyi, MD","National Cancer Institute (NCI)","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","+380638760185","alekseydobrzhanskiy@gmail.com",[23],{"facility":24,"status":25,"city":26,"state":10,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"National Cancer Institute","RECRUITING","Kyiv","03022","Ukraine","UA",{"type":31,"coordinates":32},"Point",[33,34],30.5238,50.45466,{"lat":34,"lon":33},[37,39,42,44],{"name":38,"role":19,"phone":20,"phoneExt":10,"email":21},"Oleksii Dobrzhanskyi",{"name":40,"role":41,"phone":10,"phoneExt":10,"email":10},"Yurii Kondratskyi, MD, PhD","SUB_INVESTIGATOR",{"name":43,"role":41,"phone":10,"phoneExt":10,"email":10},"Mykyta Pepenin, MD",{"name":45,"role":41,"phone":10,"phoneExt":10,"email":10},"Andrii Horodetskyi, MD",{"type":16,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Oleksii Dobrzhanskiy","Surgical oncoligist","100615640","impact-of-endo-vac-therapy-for-esophago-jejunal-anastomotic-leak-100615640",false,"NCT07295236","Impact of Endo-vac Therapy for Esophago-jejunal Anastomotic Leak","Prospective Observational Study on Endo-vac Therapy for Esophago-jejunal Anastomotic Leak","ENDO-VAL","Inclusion Criteria:\n\n* patients who developed esophago-jejunal anastomotic leak less than 50% of circumference of anastomosis\n* patients who developed esophago-jejunal anastomotic leak and remained stable at the moment of diagnosis with no indications for diversion surgery\n\nExclusion Criteria:\n\n* unstable patients who developed esophago-jejunal anastomotic leak\n* patients who developed esophago-jejunal anastomotic leak more than 50% or anastomotic circumference\n* patients who rejected endoscopic vacuum therapy","ALL","18 Years","90 Years",{"count":61,"type":62},100,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to assess the impact of endoscopic vacuum therapy in patients who underwent total gastrectomy due to gastric cancer and developed esophago-jejunal anastomotic leakage. The main outcomes to be investigated are the following:\n\nPrimary endpoint: mortality rate Secondary endpoints: morbidity rate, time from AL diagnosis to discharge, patients satisfactory rate.",[67],"Esophagojejunal Anastomotic Leak",[69,70,71,72],"gastric cancer","esophagojejunal anastomotic leak","total gastrectomy","Endoscopic vacuum therapy","2025-12-21",{"date":75,"type":76},"2025-12-29","ACTUAL",{"date":78,"type":76},"2025-12-01",{"date":80,"type":62},"2035-12-01",{"name":5,"class":6},1]